NCT00200200View on ClinicalTrials.gov

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

November 19, 2004

Primary Completion Date

March 13, 2025

Study Completion Date

March 13, 2025

Conditions
Hepatic MetastasesColon CancerRectal Cancer
Interventions
DRUG

Bevacizumab HAI plus systemic chemotherapy

Oxaliplatin (mg/m2) IV, over 2 hours, 5 FU (mg/m2) continuous infusion, over two days, leucovorin (mg/m2) IV, over 2 hours

DRUG

HAI plus systemic chemotherapy

Irinotecan (mg/m2) IV, over 30 minutes, 5 FU (mg/m2) continuous infusion over two days, leucovorin (mg/m2) IV, over 30 minutes

Trial Locations (5)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester (Follow Up Only), Harrison

11553

Memorial Sloan Kettering Nassau (Follow Up Only), Uniondale

11725

Memorial Sloan Kettering Cancer Commack (Follow Up Only), Commack

Unknown

Memorial Sloan Kettering Basking Ridge (Follow Up Only), Basking Ridge

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00200200 - Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer | Biotech Hunter | Biotech Hunter